Serum untargeted metabolomic changes in response to diet intervention in dogs with preclinical myxomatous mitral valve disease

Myocardial energy deprivation plays a causal role in the development of heart failure. A cardiac protection blend (CPB) of nutrients including medium chain triglycerides, fish oil and other key nutrients was developed to slow the progression of canine myxomatous mitral valve disease (MMVD). A six-month dietary intervention demonstrated efficacy of CPB in slowing MMVD progression. Untargeted metabolomic analysis of serum from these dogs identified 102 differential metabolites (adjusted P < 0.05). The ratios of omega-6 to omega-3 fatty acid (FA) changed from 2.41 and 1.46 in control and CPB groups at baseline to 4.30 and 0.46 at 6 months respectively. A 2.7-fold increase of α-aminobutyrate, a myocardial modulator of glutathione homeostasis, was found in CPB dogs compared to 1.3-fold increase in control dogs. Arginine and citrulline, precursors of nitric oxide biosynthesis, were both increased 2-fold; caprate, a medium chain FA, was increased 3-fold; and deoxycarnitine, precursor of carnitine biosynthesis, was increased 2.5-fold in CPB dogs. Margarate and methylpalmitate decreased in response to CPB, a potential benefit in MMVD dogs as positive correlations were found between changes in both these FAs and left atrial diameter (r = 0.69, r = 0.87 respectively, adjusted P < 0.05). Sphingomyelins with very long chain saturated FAs associated with decreased risk of heart failure in humans were increased in MMVD dogs fed the CPB diet. Our data supports the hypothesis that CPB improves FA utilization and energetics, reduces oxidative stress and inflammation in MMVD dogs. More studies are needed to understand the roles of specific metabolites in MMVD.

[1]  P. E. Verkade,et al.  Researches on fat metabolism. II. , 1934, The Biochemical journal.

[2]  F. Kunz,et al.  Plasma phosphatidylethanolamine--a better indicator in the predictability of atherosclerotic complications? , 1971, Atherosclerosis.

[3]  A. Bach,et al.  Effect of the Fatty Acid Composition of Ingested Fats on Rat Liver Intermediary Metabolism , 1976, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[4]  A. Bach,et al.  Ketogenic response to medium-chain triglyceride load in the rat. , 1977, The Journal of nutrition.

[5]  A. Bach,et al.  Medium-chain triglycerides: an update. , 1982, The American journal of clinical nutrition.

[6]  L. Sartorelli,et al.  On the transport mechanisms of carnitine and its derivative in rat heart slices. , 1982, The Italian journal of biochemistry.

[7]  R. Gross Identification of plasmalogen as the major phospholipid constituent of cardiac sarcoplasmic reticulum. , 1985, Biochemistry.

[8]  H. Kaunitz Medium chain triglycerides (MCT) in aging and arteriosclerosis. , 1986, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[9]  L. Sartorelli,et al.  Myocardial carnitine transport. , 1987, Basic research in cardiology.

[10]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[11]  P. J. Jones,et al.  Medium chain fatty acid metabolism and energy expenditure: obesity treatment implications. , 1998, Life sciences.

[12]  H. Pedersen,et al.  Mitral valve prolapse in the dog: a model of mitral valve prolapse in man. , 2000, Cardiovascular research.

[13]  C. Colton,et al.  Mechanisms of the antioxidant effects of nitric oxide. , 2001, Antioxidants & redox signaling.

[14]  R. Wanders,et al.  Carnitine biosynthesis in mammals. , 2002, The Biochemical journal.

[15]  A. Simopoulos,et al.  The importance of the ratio of omega-6/omega-3 essential fatty acids. , 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  C. Roe,et al.  Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. , 2002, The Journal of clinical investigation.

[17]  Douglas M. Hawkins,et al.  A variance-stabilizing transformation for gene-expression microarray data , 2002, ISMB.

[18]  J. Blumberg,et al.  Antioxidant status and biomarkers of oxidative stress in dogs with congestive heart failure. , 2005, Journal of veterinary internal medicine.

[19]  K. Naseem The role of nitric oxide in cardiovascular diseases. , 2005, Molecular aspects of medicine.

[20]  D. Matern,et al.  Fetal Fatty Acid Oxidation Disorders, Their Effect on Maternal Health and Neonatal Outcome: Impact of Expanded Newborn Screening on Their Diagnosis and Management , 2005, Pediatric Research.

[21]  T. Lüscher,et al.  Nitric Oxide in Hypertension , 2006, Journal of clinical hypertension.

[22]  R. A. van den Berg,et al.  Centering, scaling, and transformations: improving the biological information content of metabolomics data , 2006, BMC Genomics.

[23]  S. Chittur,et al.  Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease. , 2006, American journal of veterinary research.

[24]  Stefan Neubauer,et al.  The failing heart--an engine out of fuel. , 2007, The New England journal of medicine.

[25]  B. Fielding,et al.  Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. , 2008, Progress in lipid research.

[26]  C. Des Rosiers,et al.  Medium-chain Fatty Acids as Metabolic Therapy in Cardiac Disease , 2008, Cardiovascular Drugs and Therapy.

[27]  A. Simopoulos,et al.  The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases , 2008, Experimental biology and medicine.

[28]  C. Hoppel,et al.  Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. , 2009, The Journal of nutrition.

[29]  A. Lochner,et al.  Nitric oxide in the cardiovascular system: a simple molecule with complex actions , 2009, Cardiovascular journal of Africa.

[30]  L. Freeman Beneficial effects of omega-3 fatty acids in cardiovascular disease. , 2010, The Journal of small animal practice.

[31]  R. Wanders,et al.  Fatty acid omega‐oxidation as a rescue pathway for fatty acid oxidation disorders in humans , 2011, The FEBS journal.

[32]  F. Recchia,et al.  Modulating fatty acid oxidation in heart failure. , 2011, Cardiovascular research.

[33]  W. Kraus,et al.  Metabolic profiles predict adverse events after coronary artery bypass grafting. , 2012, The Journal of thoracic and cardiovascular surgery.

[34]  A. Abdel-Naim,et al.  Anti-inflammatory activity of methyl palmitate and ethyl palmitate in different experimental rat models. , 2012, Toxicology and applied pharmacology.

[35]  William E. Kraus,et al.  Metabolomic Profiling for the Identification of Novel Biomarkers and Mechanisms Related to Common Cardiovascular Diseases: Form and Function , 2012, Circulation.

[36]  E. Riboli,et al.  Plasma Phospholipid Fatty Acid Concentration and Incident Coronary Heart Disease in Men and Women: The EPIC-Norfolk Prospective Study , 2012, PLoS medicine.

[37]  Torsten Doenst,et al.  Cardiac Metabolism in Heart Failure: Implications Beyond ATP Production , 2013, Circulation research.

[38]  Stephen T. C. Wong,et al.  Mechanical Unloading Promotes Myocardial Energy Recovery in Human Heart Failure , 2014, Circulation. Cardiovascular genetics.

[39]  M. Kuzuya,et al.  Oral supplementation with a combination of L-citrulline and L-arginine rapidly increases plasma L-arginine concentration and enhances NO bioavailability. , 2014, Biochemical and Biophysical Research Communications - BBRC.

[40]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[41]  Rick B. Vega,et al.  Energy Metabolic Reprogramming in the Hypertrophied and Early Stage Failing Heart: A Multisystems Approach , 2014, Circulation. Heart failure.

[42]  M. Schulze,et al.  Association between erythrocyte membrane fatty acids and biomarkers of dyslipidemia in the EPIC-Potsdam study , 2014, European Journal of Clinical Nutrition.

[43]  D. Argyle,et al.  Gene network and canonical pathway analysis in canine myxomatous mitral valve disease: a microarray study. , 2015, Veterinary journal.

[44]  Rick B. Vega,et al.  Mitochondrial biogenesis and dynamics in the developing and diseased heart , 2015, Genes & development.

[45]  David S. Wishart,et al.  MetaboAnalyst 3.0—making metabolomics more meaningful , 2015, Nucleic Acids Res..

[46]  S. Hannah,et al.  Veterinary Medicine and Multi-Omics Research for Future Nutrition Targets: Metabolomics and Transcriptomics of the Common Degenerative Mitral Valve Disease in Dogs. , 2015, Omics : a journal of integrative biology.

[47]  A. Koulman,et al.  A Review of Odd-Chain Fatty Acid Metabolism and the Role of Pentadecanoic Acid (C15:0) and Heptadecanoic Acid (C17:0) in Health and Disease , 2015, Molecules.

[48]  Rick B. Vega,et al.  The Failing Heart Relies on Ketone Bodies as a Fuel , 2016, Circulation.

[49]  K. Margulies,et al.  Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure , 2016, Circulation.

[50]  D. El-Agamy,et al.  Modulation of cyclophosphamide-induced cardiotoxicity by methyl palmitate , 2017, Cancer Chemotherapy and Pharmacology.

[51]  K. Hirata,et al.  2-Aminobutyric acid modulates glutathione homeostasis in the myocardium , 2016, Scientific Reports.

[52]  J. Zavadil,et al.  Mitral valve prolapse is associated with altered extracellular matrix gene expression patterns. , 2016, Gene.

[53]  V. Macrae,et al.  Comparative Transcriptomic Profiling and Gene Expression for Myxomatous Mitral Valve Disease in the Dog and Human , 2017, Veterinary sciences.

[54]  Ismael Saifudeen,et al.  Metabolic Modulation by Medium-Chain Triglycerides Reduces Oxidative Stress and Ameliorates CD36-Mediated Cardiac Remodeling in Spontaneously Hypertensive Rat in the Initial and Established Stages of Hypertrophy. , 2017, Journal of cardiac failure.

[55]  Öztun Temelli,et al.  Postoperative Radiotherapy in Salivary Gland Carcinoma: A Single Institution Experience. , 2017, The Gulf journal of oncology.

[56]  Y. Pinto,et al.  Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients. , 2017, JACC. Heart failure.

[57]  D. Mozaffarian,et al.  Circulating Very Long‐Chain Saturated Fatty Acids and Heart Failure: The Cardiovascular Health Study , 2018, Journal of the American Heart Association.

[58]  Scott B. Crown,et al.  Cardiovascular Metabolomics , 2018, Circulation research.

[59]  Jung-Wan Kim,et al.  An evidence of C16 fatty acid methyl esters extracted from microalga for effective antimicrobial and antioxidant property. , 2018, Microbial pathogenesis.

[60]  R. Vasan,et al.  Ceramide Remodeling and Risk of Cardiovascular Events and Mortality , 2018, Journal of the American Heart Association.

[61]  D. Priolli,et al.  Plasmalogen lipids: functional mechanism and their involvement in gastrointestinal cancer , 2018, Lipids in Health and Disease.

[62]  Qinghong Li,et al.  Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs , 2019, BMC veterinary research.

[63]  D. Mozaffarian,et al.  Plasma Ceramides and Sphingomyelins in Relation to Heart Failure Risk. , 2019, Circulation. Heart failure.

[64]  Jing Wang,et al.  Disturbed energy and amino acid metabolism with their diagnostic potential in mitral valve disease revealed by untargeted plasma metabolic profiling , 2019, Metabolomics.

[65]  R. Levy,et al.  Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms. , 2020, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[66]  Jacob E. Wulff,et al.  Precision of a Clinical Metabolomics Profiling Platform for Use in the Identification of Inborn Errors of Metabolism. , 2020, The journal of applied laboratory medicine.